Spencer Pharmaceutical Inc.
Other OTCTotal Valuation
Spencer Pharmaceutical Inc. carries a market capitalization of 29,436.00, placing it among publicly traded companies globally.
| Market Cap | 29,436.00 |
| Enterprise Value | N/A |
Share Statistics
Spencer Pharmaceutical Inc. currently has 1.34M shares outstanding.
| Shares Outstanding | 1.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Spencer Pharmaceutical Inc. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.53 |
| Quick Ratio | 0.37 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -42.92 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Spencer Pharmaceutical Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Spencer Pharmaceutical Inc. generated 670,214.00 in revenue and converted that into -1.24M in net income, yielding earnings per share of -1.61. EBITDA reached -1.30M, while operating income came in at -1.33M.
| Revenue | 670,214.00 |
| Gross Profit | 90,083.00 |
| Operating Income | -1.33M |
| Pretax Income | -509,685.00 |
| Net Income | -1.24M |
| EBITDA | -1.30M |
| EBIT | -1.33M |
| Earnings Per Share (EPS) | -1.61 |
Balance Sheet
Total book value stands at -5.14M, with working capital of -829,933.00 providing operational flexibility.
| Cash & Cash Equivalents | 2,832.00 |
| Total Debt | N/A |
| Net Debt | 538,614.00 |
| Equity (Book Value) | -5.14M |
| Book Value Per Share | -6.13 |
| Working Capital | -829,933.00 |
Cash Flow
Spencer Pharmaceutical Inc. produced -635,304.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -635,304.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -635,304.00 |
| FCF Per Share | -0.76 |
Margins
Spencer Pharmaceutical Inc. operates with a gross margin of 13.44, reflecting its pricing power and cost economics. The operating margin of -199.04 and net profit margin of -184.63 provide insight into operational efficiency.
| Gross Margin | 13.44 |
| Operating Margin | -199.04 |
| Pretax Margin | -76.05 |
| Profit Margin | -184.63 |
| EBITDA Margin | -193.94 |
Stock Splits
Spencer Pharmaceutical Inc.'s most recent stock split took place on October 5, 2009 with a 25:1 split ratio.
| Last Split Date | 10/5/2009 |
| Split Ratio | 25:1 |
Scores
Spencer Pharmaceutical Inc. posts an Altman Z-Score of -5.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.50 |